DOCSLIB.ORG

Copyrighted Material

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Copyrighted Material INDEX Note: Italicized page locators indicate figures/photos; tables are noted with t. AASLD. See American Association for molecular characteristics and ACE genotype, heart failure and, 486 the Study of Liver Diseases therapeutic use, 582t ACE genotype D, 486 AAV. See Adeno-associated virus other applications and additional ACE inhibitors. See Angiotensin- Abatacept (Orencia) information, 166 converting enzyme (ACE) clinical pharmacology, 164 pharmacokinetics, 165 inhibitors dosage form, 163 recommended dosage and Acel-Imune (diphtheria and tetanus dosage form, pharmacokinetics, and monitoring requirements, 165 toxoids and acellular pertussis disposition data, 556t role in therapy, 166 vaccine adsorbed) drug interactions, 164 route of administration, 165 dosage form, pharmacokinetics, and general description, 163 target, product type, indications, disposition data, 576t indications and use, 163 FDA approval year, 148t molecular characteristics and molecular characteristics and therapeutic response, 166 therapeutic use, 612t therapeutic use, 582t ABC transporters, protein, feature, and ACIP. See Advisory Committee for other applications, 165 total number of genes, 527t Immunization Practices pharmacokinetics, 164 Abelcet, 452 Acoustic filters, perfusion recommended dosing and Abilify, off-label promotion of, configurations and, 70 monitoring requirements, 163 settlement involving, 119t Acquired disorders, gene and cell role in therapy, 164 Abrin, construction of immunotoxins therapy and, 497, 497t route of administration, 163 and, 455, 455t ACR. See American College of target, product type, indications, Absorption, distribution, metabolism, Rheumatology FDA approval year, 148t and elimination Acromegaly therapeutic response, 164 new drugs and, 521 refractory, Somavert in treatment of, Abbott, revenue, market share, new molecular entities and, 14 348, 349 productivity, and research preclinical studies and, 108 Sandostatin in treatment for, 346 investments of, 5t Absorption, of recombinant protein Somatuline Depot in treatment of, Abbreviated new drug applications, pharmaceuticals, 85–86, 100 33, 340 111, 116–117 Absorption rate SST analogs and treatment of, 312 Abbreviations prescription drugs and, 80 Acrylated Fv products, recombinant, for common amino acids, COPYRIGHTEDsymbol, mathematical relationship, MATERIAL 458 623t–625t and physiological variables, 83 ACT. See Adoptive cell therapy explanation for, 626t–631t ACA. See Affordable Care Act Actemra (tocilizumab), 156 Abciximab (ReoPro), 147, 227 Academy of Managed Care Pharmacy, dosage form, 206 clinical pharmacology, 165 541 dosage form, pharmacokinetics, and dosage form, 165 Accelerated approval, 114 disposition data, 562t dosage form, pharmacokinetics, and Accelerated development and review indications and use, 206 disposition data, 556t process, use of, 107, 108 molecular characteristics and drug interactions, 165 Accupril (quinapril), restenosis after therapeutic use, 590t general description, 165 stent implantation and, 486 recommended dosage and indications and use, 165 ACE D allele, 486 monitoring requirements, 206 Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs, Second Edition. Rodney J. Y. Ho. © 2013 John Wiley & Sons, Inc. Published 2013 by John Wiley & Sons, Inc. 633 Chapter No.: 3 Title Name: RodneyJHo Comp. by: TSanthosh Date: 20 Aug 2013 Time: 01:44:57 AM Stage: Printer Page Number: 633 0002007355.INDD 633 8/20/2013 1:44:57 AM 634 INDEX Actemra (tocilizumab) (cont’d) molecular characteristics and for severe combined role in therapy, 206 therapeutic use, 591t immunodeficiency, 361 route of administration, 206 ADA gene, 361 ADH. See Antidiuretic hormone target, product type, indications, Adagen (PEG-ADA), 447 ADH1 gene, ADH isoenzymes FDA approval year, 149t Adagen (pegademase bovine) encoded by, 481 ACTH. See Adrenocorticotropic dosage form, 381 ADH2 gene, ADH isoenzymes hormone indications and use, 381 encoded by, 481 ActHIB (Haemophilus b conjugate role in therapy, 382 ADH3 gene, ADH isoenzymes vaccine, tetanus toxoid route of administration, 381 encoded by, 481 conjugate) Adalimumab (Humira) Adipocytes, 90, 213 dosage form, pharmacokinetics, and clinical pharmacology, 167 Adjuvants, vaccine, 398, 400, 405 disposition data, 577t dosage form, 167 Adjuvant systems, novel, and vaccine molecular characteristics and dosage form, pharmacokinetics, and delivery technologies, 400t therapeutic use, 613t disposition data, 556t ADME. See Absorption, distribution, Actimmune (interferon gamma 1b) drug interactions, 167 metabolism, and elimination dosage form, 300 general description, 166 Adoption of new therapies and dosage form, pharmacokinetics, and indications and use, 166 medicines, 536 disposition data, 574t molecular characteristics and Adoptive cell therapy, metastatic indications and use, 300 therapeutic use, 582t melanoma and, 505–506 molecular characteristics and other applications and additional Adrenocorticotropic hormone, sources therapeutic use, 608t information, 168 and clinical use of, 309t off-label promotion of, settlement pharmacokinetics, 167 Advanced Cell Technology, 510 involving, 118, 119t recommended dosage and Advate (antihemophilic factor recommended dosage and monitoring requirements, 167 (recombinant), plasma/albumin monitoring requirements, 300 role in therapy, 168 free) role in therapy, 301 route of administration, 167 dosage form, pharmacokinetics, and route of administration, 300 sponsors, indications, annual sales in disposition data, 565t Activase (alteplase), 33 millions, 6t molecular characteristics and clinical pharmacology, 374 target, product type, indications, therapeutic use, 594t dosage form, 373 FDA approval year, 148t Advate (antihemophilic factor VIII) dosage form, pharmacokinetics, and therapeutic response, 168 dosage form, 232 disposition data, 563t Adaptive immunity, 393 general description, 231–232 indications and use, 373 ADA-SCID, 506 indications and use, 232 molecular characteristics and ADCC. See Antibody-dependent pharmacokinetics, 233 therapeutic use, 592t cellular cytotoxicity recommended dosage and recommended dosage and monitoring Adcetris (brentuximab vedotin) monitoring requirements, requirements, 373–374 dosage form, 177 232–233 role in therapy, 374 dosage form, pharmacokinetics, and route of administration, 232 route of administration, 373 disposition data, 557t Adverse drug reactions, 96, 474 Activated V (Va) calcium, 225 drug interactions, 177 Advexin, 506 Activin A, 511, 511t indications and use, 176–177 Advisory Committee for Immunization Acute coronary syndrome molecular characteristics and Practices aptamer-based therapies and, 497 therapeutic use, 583t on bivalent HPV vaccine, 411 Integrilin in treatment of, 241 recommended dosage and on hepatitis B vaccine, 410 Acute lymphoblastic leukemia, monitoring requirements, 177 on quadrivalent HPV vaccine, 411 Leukine in treatment of, 249 role in therapy, 177 on varicella vaccine, 415 Acute myelogenous leukemia, Leukine route of administration, 177 on Zostavax, 416 in treatment of, 249 target, product type, indications, Affordable Care Act, biosimilars and, Acute myeloid leukemia, aptamer- FDA approval year, 149t 133, 134 based therapies and, 497 ADCs. see Antibody-drug conjugates Aflibercept (Eylea) Acute myocardial infarction Adefovir dipivoxil (Hepsera), 273 clinical pharmacology, 168–169 Activase in treatment of, 373, 374 Adeno-associated virus, 500 disposition, 169 Retavase in treatment of, 385, 386 as gene therapy for hemophilia, 503, dosage form, 168 TNKase in treatment of, 386, 387 504 dosage form, pharmacokinetics, and Acyclovir, 9, 9, 97 Adenosine deaminase (Adagen), 449, 506 disposition data, 556t Acylated insulin derivatives, 462 clearance and, 447 general description, 168 ADA. See Adenosine deaminase dosage form, pharmacokinetics, and indications and use, 168 Adagen (adenosine deaminase) disposition data, 562t molecular characteristics and dosage form, pharmacokinetics, and molecular characteristics and therapeutic use, 582t disposition data, 562t therapeutic use, 591t pharmacokinetics, 169 Chapter No.: 3 Title Name: RodneyJHo Comp. by: TSanthosh Date: 20 Aug 2013 Time: 01:44:57 AM Stage: Printer Page Number: 634 0002007355.INDD 634 8/20/2013 1:44:57 AM INDEX 635 recommended dosage and dosage form, 288 target, product type, indications, monitoring requirements, 168 dosage form, pharmacokinetics, and FDA approval year, 148t role in therapy, 169 disposition data, 573t therapeutic response, 171 route of administration, 168 drug interactions, 289 Alendronate (Fosamax), 315 therapeutic response, 169 general description, 288 Alferon-N (interferon alfa-n3, human Africa, sub-Saharan, social indications and use, 288 leukocyte derived) entrepreneurs and conjugated molecular characteristics and dosage form, pharmacokinetics, and meningococcal vaccine for, 21 therapeutic use, 607t disposition data, 573t African American men, SRD5A2 and other applications and additional molecular characteristics and risk of prostate cancer in, 484 information, 289 therapeutic use, 608t African Americans, primaquine- pharmacokinetics, 289 Alglucerase (Ceradase) mediated hemolysis symptom recommended dosage and dosage form, pharmacokinetics, and and, 473 monitoring requirements, 289 disposition data, 562t Agalsidase, for Fabry’s disease, 363 role in therapy, 289 molecular characteristics and Agalsidase beta (Fabrazyme), 363 route of administration, 289 therapeutic use, 591t clinical pharmacology, 371 therapeutic response, 289 Alglucosidase,
Load more

Recommended publications
  • Bovine Somatotropin in Milk
    Utah State University DigitalCommons@USU Archived Food and Health Publications Archived USU Extension Publications 1999 Bovine Somatotropin in Milk Charlotte P. Brennand PhD Utah State University Extension Clell V. Bagley DVM Utah State University Follow this and additional works at: https://digitalcommons.usu.edu/extension_histfood Part of the Animal Sciences Commons, Food Processing Commons, and the Nutrition Commons Warning: The information in this series may be obsolete. It is presented here for historical purposes only. For the most up to date information please visit The Utah State University Cooperative Extension Office Recommended Citation Brennand, Charlotte P. PhD and Bagley, Clell V. DVM, "Bovine Somatotropin in Milk" (1999). Archived Food and Health Publications. Paper 32. https://digitalcommons.usu.edu/extension_histfood/32 This Factsheet is brought to you for free and open access by the Archived USU Extension Publications at DigitalCommons@USU. It has been accepted for inclusion in Archived Food and Health Publications by an authorized administrator of DigitalCommons@USU. For more information, please contact [email protected]. EL 250.6 UTAH STATE UNIVERSITY COOPERATIVE EXTENSION FOOD SAFETY FACT 8UEET m1888 FOOD SAFTBY SBRIBS by Charlotte P. Brennand, PhD Clell V. Bagley, DVM Extension Food Safety Specialist Extension Veterinarian Bovine Somatotropin in Milk What is Bovine Sources of BST/BGH Biotechnology Somatotropin? production of BST Early research efforts used crude extracts from bovine pituitary Bovine Somatotropin (BST), The genes responsible for pro­ glands. Although the treated cows also called bovine growth hormone duction of BST in cattle were iden­ increased their milk production, the (BGH), is a hormone produced by tified in bovine tissue cells; they amount of available BST was too the cow's pituitary gland.
    [Show full text]
  • Bovine Somatotropin (Bst) – Possible Increased Use of Antibiotics to Treat Mastitis in Cows, October 30, 2013
    Bovine Somatotropin (bST) – Possible Increased Use of Antibiotics to Treat Mastitis in Cows, October 30, 2013 Suzanne J. Sechen, Ph.D. Leader, Ruminant Drugs Team Division of Production Drugs Office of New Animal Drug Evaluation Center for Veterinary Medicine, Food and Drug Administration Rockville, MD, U.S.A. The following report was submitted by FDA’s Center for Veterinary Medicine for consideration in the re-evaluation of bovine somatotropin at the seventy-eighth meeting on residues of veterinary drugs by the Joint FAO/WHO Expert Committee (JECFA) on Food Additives, held November 5-14, 2013 BACKGROUND The United States Food and Drug Administration (FDA) approved a formulation of recombinant bovine growth hormone (bST) in 1993, sometribove zinc, for administration to lactating dairy cows to increase milk production. The FDA concluded that use of the drug increased the risk of clinical mastitis in treated cows, and that it may also increase milk somatic cell count1. Approved labeling for the product communicates these risks. These conclusions were reconfirmed in 2003 when the FDA approved a supplemental application for this bST product following reanalysis by the sponsor of the original data and new, post- approval monitoring program (PAMP) data using more accurate mixed-model analyses, not available at the time of the original approval2. At the time of the original approval, FDA concluded that the increase in clinical mastitis in sometribove-treated cows was not a public health concern in terms of antibiotic residues in milk being increased above tolerance due to therapeutic treatment of mastitis1. When examined on a per unit milk basis, the increase in the incidence of clinical mastitis due to sometribove (approximately 0.1 case per cow per year) was about 4 to 9 times less than the effects due to other sources of variation, such as season, parity, stage of lactation, and herd-to-herd variation.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Somatotropin Physiology
    S.Afr.J.Anim.Sci.,199 4, 24(1) Somatotropinphysiology - a review J.G.van der Walt Departmentof Physiology,Veterinary Science, University of Pretoria,Onderstepoort, 0110 Republicof SouthAf rica Received4 June 1993;accepted l5 November/,993 The continuing search for improved efficiency has led to the introduction of exogenousgrowth and lactation promo- tants to enhance traditional animal production systems.Various species-limitedsomatotropins have been synthesized by meansof recombinantgene technology,thereby allowing milk productionin dairy cattle,and lcan meat production in pigs, sheep and cattle to be manipulated.Growth hormone occurs in plasma in several forms, which overlap considerably with the structuresof placental lactogen and prolactin. The peptide is stabilized by two disulphidc bridges,and is folded into four a-helix regions.The somatogenicand lactogenicregions have been mapped,and two different binding sites found. Somatotropinis secretedepisodically from the anterior pituitary with a sniking ultradian rhythm in all mammals investigated thus far. The primary control over this release would appear to be neuro- endocrinological,with somatostatinand releasinghormone (GHRH) playing the major roles, with considerablespecics differences.Starvation primes the systemto optimally releasesomatotropin when feedingrecommences. While sexual dimorphism in the releaseof somatotropinhas been clearly demonstratedin the rat, most studiesin other specieshave concentratedon male animals. Although somatotropinexhibis negative feedback on its release,it
    [Show full text]
  • The Role of Somatostatin in the Regulation of Gonadotropin Secretion in Sheep
    Graduate Theses, Dissertations, and Problem Reports 2017 The Role of Somatostatin in the Regulation of Gonadotropin Secretion in Sheep Richard B. McCosh Follow this and additional works at: https://researchrepository.wvu.edu/etd Recommended Citation McCosh, Richard B., "The Role of Somatostatin in the Regulation of Gonadotropin Secretion in Sheep" (2017). Graduate Theses, Dissertations, and Problem Reports. 6194. https://researchrepository.wvu.edu/etd/6194 This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. The Role of Somatostatin in the Regulation of Gonadotropin Secretion in Sheep Richard B. McCosh Dissertation submitted to the School of Medicine at West Virginia University in partial fulfillment of the requirements for the degree of Doctor of Philosophy In Biomedical Science Cellular and Integrative Physiology Robert L. Goodman, PhD; Mentor Stanley M. Hileman, PhD; Chair Michael W. Vernon, PhD Steven L. Hardy, PhD Donal C. Skinner, PhD Department of Physiology and Pharmacology Morgantown, West Virginia 2017 Key Words: gonadotropin releasing hormone, luteinizing hormone, somatostatin, kisspeptin, sheep Copyright 2017 Richard B.
    [Show full text]
  • This Thesis Has Been Approved by the Honors Tutorial College and Department of Biological Sciences
    This thesis has been approved by The Honors Tutorial College and Department of Biological Sciences ___________________________________ Dr. Darlene Berryman Professor, School of Applied Health Sciences and Wellness College of Health Sciences and Professions Thesis Adviser __________________________________ Dr. Soichi Tanda Director of Studies, Honors Tutorial College Biological Sciences _________________________________ Jeremy Webster Dean, Honors Tutorial College THE EFFECT OF GROWTH HORMONE ON THE MACROPHAGE CONTENT OF DIFFERENT ADIPOSE TISSUE DEPOTS A Thesis Presented to The Honors Tutorial College Ohio University _____________________________________________ In Partial Fulfillment Of the Requirements for Graduation From the Honors Tutorial College With the Degree of Bachelor of Science in Biological Sciences _____________________________________________ By Rachel D Munn June 2011 1 Table of Contents Acknowledgements…………………………………………………3 Abstract……………………………………………………………...4 Introduction…………………………………………………………6 Adipose Tissue………………………………………………6 Adipose Tissue Depots……………………………………...7 Obesity………………………………………………………11 Inflammation………………………………………………..12 Macrophages………………………………………………..14 Physiological Function……………………………...14 Adipose Tissue Macrophages……………………….15 Growth Hormone……………………………………………18 Function……………………………………………..19 Growth Hormone and Macrophages………………..23 Growth Hormone and Adipose……………………...24 Transgenic Mouse Models…………………………………..26 Significance of Research…………………………………….29 Materials and Methods…………………………………………….30 Results……………………………………………………………….36
    [Show full text]
  • Effects of Plasmid Growth Hormone–Releasing Hormone Treatment During Heat Stress
    DNA AND CELL BIOLOGY Volume 27, Number 11, 2008 ª Mary Ann Liebert, Inc. Pp. 629–635 DOI: 10.1089=dna.2008.0758 Effects of Plasmid Growth Hormone–Releasing Hormone Treatment during Heat Stress Patricia A. Brown,1 Angela M. Bodles-Brakhop,2 and Ruxandra Draghia-Akli2 A gene therapy treatment with plasmid-based growth hormone–releasing hormone (GHRH) delivered by elec- troporation (EP) was investigated during heat stress; 32 primiparous cows received 2.5 mg of a GHRH-expressing myogenic plasmid (pSP-HV-GHRH), while 20 were designated as controls. Offspring of treated animals showed a reduction in mortality (47%; p < 0.02), and survival from birth to 260 days was dramatically improved (0% mortality vs. 21% in controls) along with an increase in weight gain ( p < 0.05). Milk production was increased compared to controls with an average yield gain of 421 kg=cow ( p ¼ 0.028). Prolactin (PRL) levels were also significantly increased compared to controls ( p < 0.05). The second pregnancy rate was improved by GHRH treatment (53.3% vs. 30.8%). This study shows that the use of plasmid-mediated therapy delivered by EP can maintain health status during periods of heat stress, important for both animals and potentially humans in hot, challenging climates. tion of bovine somatotropin (bST) is the current method used Introduction to improve productivity in domestic animals and has been he seasons of the year can have a dramatic impact on shown to enhance milk production (Gulay et al., 2003, 2004) Thumans and animals alike. As a model for heat stress we even under conditions of heat stress (Johnson et al., 1991; have chosen dairy cows.
    [Show full text]
  • CURRICULUM VITAE PERSONAL INFORMATION Name: David Robert Clemmons EDUCATION 1965-1966 Undergraduate, Vanderbilt University 1966
    CURRICULUM VITAE PERSONAL INFORMATION Name: David Robert Clemmons EDUCATION 1965-1966 Undergraduate, Vanderbilt University 1966-1969 B.S., Davidson College 1970-1974 M.D. with honors, University of North Carolina at Chapel Hill Postgraduate: 1974-1975 Intern in Medicine, Massachusetts General Hospital 1975-1976 Junior Assistant Resident, Massachusetts General Hospital 1976-1977 Senior Assistant Resident, Johns Hopkins Hospital 1977-1978 Clinical Fellowship in Endocrinology, Massachusetts General Hospital 1978-1980 Research Fellow in Cell Biology, Massachusetts General Hospital and the University of North Carolina at Chapel Hill RESEARCH EXPERIENCE 1971-1972 USPHS Fellow in Pediatric Endocrinology 1978-1980 USPHS Fellow in Endocrinology FACULTY APPOINTMENTS 1980-1984 Assistant Professor of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 1984-1989 Associate Professor of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 1989-present Professor of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 1990-2006 Chief, Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, NC 1995-present Sarah Graham Kenan Professor of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 2006-2009 Director, Diabetes Center for Excellence, University of North Carolina School of Medicine, Chapel Hill, NC TEACHING APPOINTMENTS 1974-1976 Clinical Fellow in Medicine, Harvard Medical School 1976-1977 Clinical Fellow in Medicine, Johns Hopkins Hospital 1977-1978 Clinical Fellow in Endocrinology, Harvard Medical School 1978-1980 Clinical and Research Fellow in Endocrinology, Harvard Medical School and the University of North Carolina at Chapel Hill HONORS 1973 Deborah Cushing Leary Award 1974 Alpha Omega Alpha 1974 M.D.
    [Show full text]
  • Recombinant Bovine Growth Hormone
    cancer.org | 1.800.227.2345 Recombinant Bovine Growth Hormone Recombinant bovine growth hormone (rBGH) is a synthetic (man-made) hormone that is marketed to dairy farmers to increase milk production in cows. It has been used in the United States since it was approved by the Food and Drug Administration (FDA) in 1993, but its use is not permitted in the European Union, Canada, and some other countries. This document summarizes what is known about the product and its potential effects on health. What is recombinant bovine growth hormone (rBGH)? The human form of growth hormone, also called somatotropin, is made by the pituitary gland. It promotes growth and cell replication. Bovine growth hormone (BGH), also known as bovine somatotropin (BST) is the natural form of this hormone in cattle. Recombinant bovine growth hormone (rBGH) or recombinant bovine somatotropin (rBST) refers to bovine growth hormone that is made in a lab using genetic technology. Some rBGH products on the market differ chemically from a cow's natural somatotropin by one amino acid. Both the natural and recombinant forms of the hormone stimulate a cow's milk production by increasing levels of another hormone known as insulin-like growth factor (IGF-1). What are the health concerns in humans? Concerns about possible health effects on humans from milk produced using rBGH have focused on 2 main issues. First, does drinking milk from rBGH-treated cows increase blood levels of growth hormone or IGF-1 in consumers? If it does, would this be expected to have any health effects in people, including increasing the risk of cancer? Several scientific reviews have 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 looked at these issues and are the main focus of this document.
    [Show full text]
  • Insulin-Like Growth Factor-I and Apoptosis As Determinants of Preimplantation Bovine Embryonic Development
    INSULIN-LIKE GROWTH FACTOR-I AND APOPTOSIS AS DETERMINANTS OF PREIMPLANTATION BOVINE EMBRYONIC DEVELOPMENT By FRANK DEAN JOUSAN A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY UNIVERSITY OF FLORIDA 2006 Copyright 2006 by Frank Dean Jousan This dissertation is dedicated to my parents and family. ACKNOWLEDGMENTS This dissertation would not have been possible without the dedication, guidance, and tireless support of Dr. Peter J. Hansen, chairman of my supervisory committee. I admire Dr. Hansen for his energy, enthusiasm, and passion that he has for science. Dr. Hansen works continuously toward the development and training of scientific minds while creating an enjoyable working environment. I am grateful for the opportunity that I had to work with Dr. Hansen and will always consider him to be an excellent mentor and great friend. Appreciation is also extended to the other members of my committee: Dr. William C. Buhi for his knowledge and support; Dr. Kenneth C. Drury for his interest and insight to my research; Dr. Karen Moore for her willingness to discuss science and dedication to providing such a high-quality embryology lecture and laboratory course; and Dr. Mats Troedsson for his willingness to allow opportunities for collaborations between our laboratories and his interesting, humorous conversations. I would like to extend my sincere thanks to the management and personnel at Central Packing Co. in Center Hill, FL, for providing the ovaries used in the majority of my experiments and to William Rembert for his assistance in collecting ovaries.
    [Show full text]
  • WO 2017/180788 Al 19 October 2017 (19.10.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/180788 Al 19 October 2017 (19.10.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every Λ 61Κ 8/02 (2006.01) A61K 45/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 8/18 (2006.01) A61P 17/18 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 8/19 (2006.01) A61Q 19/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 33/00 (2006.01) C07K 14/78 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 38/00 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (21) International Application Number: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, PCT/US20 17/027275 NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (22) International Filing Date: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 12 April 2017 (12.04.2017) TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/321,626 12 April 2016 (12.04.2016) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: ILLUSTRIS PHARMACEUTICALS, INC.
    [Show full text]
  • Effects of Polyunsaturated Fatty Acids and Bovine Somatotropin on Endocrine Function, Embryo Development, and Uterine-Conceptus Interactions in Dairy Cattle
    EFFECTS OF POLYUNSATURATED FATTY ACIDS AND BOVINE SOMATOTROPIN ON ENDOCRINE FUNCTION, EMBRYO DEVELOPMENT, AND UTERINE-CONCEPTUS INTERACTIONS IN DAIRY CATTLE By TODD RUSSELL BILBY A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY UNIVERSITY OF FLORIDA 2005 Copyright 2005 by Todd R. Bilby To my parents, Ross and Cheryl Bilby, for their endless support ACKNOWLEDGMENTS I am deeply indebted to Dr. William W. Thatcher, my supervisory committee chair. Dr. Thatcher provided endless guidance, encouragement, inspiration, and financial support. Dr. Thatcher provided me with the skills to be successful and instilled in me a passion for knowledge. I am proud of the opportunity I had to work with him and will always consider Dr. Thatcher an excellent mentor and great friend. I extend my appreciation to my committee members: Dr. Peter J. Hansen, who allowed me to use his laboratory for my final project and provided endless insight into my projects, curriculum, and overall professional development; Dr. Lokenga Badinga for his teaching in the area of nutritional physiology, and for always being willing to answer any questions; and Dr. Nasser Chegini for the use of his laboratory and invaluable contributions. All committee members provided continual support throughout my Ph.D. program. I greatly appreciate Dr. Charles Staples for his patience and guidance in working with me on my projects, editing papers, and providing knowledge on dairy cattle nutrition. I would also like to thank Dr. Staples’s graduate students: Mr. Bruno Amaral for his help with my last research project and Mrs.
    [Show full text]